NZ 602511 Disclosed is the use of an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, in the preparation of a medicament for treating psoriasis in a subject, wherein the subject exhibits a Psoriasis Area and Sensitivity Index (PASI) 75 response by at least about week 12 following initial administration of the medicament, for a first extended period of administration of at least about 4 weeks, wherein the subject exhibits a loss of response by a decrease in PASI score to less than PASI 50 following discontinuation of administration of the medicament, for at least about 12 weeks, and wherein the subject exhibits at least a PASI 75 response by about 25 days following re-administration of the medicament for a second extended period of at least about 4 weeks.
